• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,085
2,275
1,819
1,803
1,709

COUNTRY

827
638
256
247
206

CATEGORIES

  • 856
  • 184
  • 950
  • 1,127
    • 99
  • 385
  • 270
  • 252
  • 65
  • 379
  • 673
  • 1,257
  • 1,621
  • 625
  • 883
  • 1,673
  • 2,638
    • 574
    • 118
    • 550
    • 75
    • 526
    • 43
    • 505
    • 18
    • 18
    • 23
  • 505
  • 727
  • 0
  • 97

PRICE

6,631
11,254
16,937
24,673

PUBLISHED

1,611
3,141
7,005
24,673

PRODUCT TYPE

20,300
3,174
856
164
74
44
21
21
12
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 124 companies plus partners developing 167 IL-5 pathway targeting drugs in 667 developmental projects...

July 2014
FROM
Proteins in Oncology Drug Pipeline Update 2014 Proteins in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Proteins in Oncology Drug Pipeline Update 2014

This drug pipeline update covers proteins, excluding antibodies, as drugs for the treatment of cancer. There are today 326 companies plus partners developing 359 protein drugs in 667 developmental projects...

July 2014
FROM
RNAs (miRNA, RNAi & siRNA) in Oncology: Drug Pathway Analyzer 2014 RNAs (miRNA, RNAi & siRNA) in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

RNAs (miRNA, RNAi & siRNA) in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 54 RNA (miRNA, RNAi & siRNA) drugs known to affect more than 157 specific intracellular signaling pathways...

July 2014
FROM
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-6 signaling pathway activates the Jak/STAT, Ras/Raf/MAPK and PI 3-kinase signaling modules. There are today 261 companies plus partners developing 362 IL-6 pathway targeting drugs in 1210 developmental...

July 2014
FROM
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The Kit receptor signaling pathway includes activation of PI 3-kinase, Src family kinases and PLC gamma. Activating mutations in the Kit receptor are associated with several human malignancies include...

July 2014
FROM
Radiation Therapy in Oncology Drug Pipeline Update 2014 Radiation Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Radiation Therapy in Oncology Drug Pipeline Update 2014

This drug pipeline update is structured around radiolabeled drugs, radiosensitizers and radioprotective compounds. There are today 318 companies plus partners developing 333 radiation therapy drugs...

July 2014
FROM
Melanoma Drug Pipeline Update 2014 Melanoma Drug Pipeline Update 2014 - Product Thumbnail Image

Melanoma Drug Pipeline Update 2014

Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced...

July 2014
FROM
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate...

July 2014
FROM
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014

Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone. There are today 179 companies plus partners...

July 2014
FROM
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-9 signaling pathway activates Jak/STAT and MAPK signaling modules. There are today 63 companies plus partners developing 67 IL-9 pathway targeting drugs in 275 developmental projects in cancer....

July 2014
FROM
Oncology Drug Pathway Analyzer (Standard Version) Oncology Drug Pathway Analyzer (Standard Version) - Product Thumbnail Image

Oncology Drug Pathway Analyzer (Standard Version)

EXTRA: Free online updates for a year Get instant, interactive pathway modeling on more than 3,500 cancer drugs across more than 100 different cancer types. Drug targets and their pathways are the...

July 2014
FROM
Leukemia Drug Pipeline Update 2014 Leukemia Drug Pipeline Update 2014 - Product Thumbnail Image

Leukemia Drug Pipeline Update 2014

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 292 companies plus partners developing 417 leukemia drugs in 632 developmental...

July 2014
FROM
Head and Neck Cancer Drug Pipeline Update 2014 Head and Neck Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Head and Neck Cancer Drug Pipeline Update 2014

There are today 144 companies plus partners developing 160 drugs targeting head and neck cancer in development. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over...

July 2014
FROM
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014 Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014

The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC. There are today 271 companies plus partners developing 392 Leptin...

July 2014
FROM
Cancer Stem Cells Drug Pipeline Update 2014 Cancer Stem Cells Drug Pipeline Update 2014 - Product Thumbnail Image

Cancer Stem Cells Drug Pipeline Update 2014

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs...

July 2014
FROM
Brain Cancer Drug Pipeline Update 2014 Brain Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Brain Cancer Drug Pipeline Update 2014

Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases...

July 2014
FROM
Apoptosis in Oncology Drug Pipeline Update 2014 Apoptosis in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Apoptosis in Oncology Drug Pipeline Update 2014

Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis...

July 2014
FROM
Epigenetic Therapy in Oncology Drug Pipeline Update 2014 Epigenetic Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Epigenetic Therapy in Oncology Drug Pipeline Update 2014

Improper gene activation or silencing by loss of epigenetic control can lead to aberrant gene expression that can drive the development of diseases such as cancer, autoimmunity, diabetes, or neurological...

July 2014
FROM
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014

There are today 168 companies plus partners developing 222 calcium signaling pathway targeting drugs in 838 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated...

July 2014
FROM
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules. There are today 287 companies plus partners developing 411 TGF-beta receptor pathway targeting drugs in 1411 developmental...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos